Bob Arthur Lubamba, PhD., is Director of In-Vitro Toxicology at Iontox, Michigan (USA), CEO of SciBioix Consulting, Durham (USA) and Director of Mentorship program at STEM DRC Initiative (USA, DR Congo).
Dr. Lubamba earned his Ph.D. and Masters of Science (both in Pharmacology) from the Université Catholique de Louvain, Brussels (Belgium), and a Bachelor’s degree in Physiology, Biomolecular and Therapeutics from the Université François Rabelais, Tours (France). He further developed his skill set as a postdoctoral fellow at the University of North Carolina at Chapel Hill working on Pulmonary Pharmacology and Therapeutics. Dr. Lubamba worked as an independent consultant in toxicology and microfluidics-related issues in the Research Triangle Park, Durham (USA). He has had extensive Research academic experience and Leadership experience.
Dr. Lubamba’s research has focused on drug development, drug discovery, toxicology, immunology and inflammatory mechanisms in lung and liver Diseases. He has an extensive experience in translational research, respiratory diseases modeling systems and pathophysiology. He has been the Principal Investigator on many funded grants that aim to understand lung diseases and drug development. He is author of multiple journal articles and book chapter.
Dr. Lubamba is a member of European Respiratory Society, The American Heart Association, Society for Mucosal Immunology, Journal Reviewer for International Journal of Molecular Sciences, Editorial Board Member of International Journal of Immunology National Academy of Medicine, and a recipient of the Belgium Royal Academy of medicine award (Albert-Pierre – Jean DUSTIN (2003-2007)) for his work on Novel Approaches for Potential Therapy of Cystic Fibrosis. Dr. Lubamba was selected among researchers from 28 states (USA) and three countries to speak about his research on Electronic Cigarette at Harvard Medical School, Massachusetts (USA). An active and committed leader with expertise in building, coaching and driving teams.